[1] |
Lin CC, Chen CB, Wang CW, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies[J/OL]. Expert Rev Clin Immunol, 2020. [2020⁃03⁃10]. doi: 10.1080/1744666X.2020. 1740591.
|
[2] |
Pham CH, Gillenwater J, Nagengast E, et al. Etanercept is safe and efficacious for treating Stevens⁃Johnson syndrome and toxic epidermal necroylsis[J]. J Burn Care Res, 2018,39(suppl_1):S48⁃S49. doi:10.1093/jbcr/iry006.090.
|
[3] |
陈玲玲, 路丹丹, 施辛, 等. 肿瘤坏死因子α拮抗剂治疗一例伴嗜酸性粒细胞增多和系统症状药疹的临床观察[J]. 中华皮肤科杂志, 2013,46(9):621⁃625. doi: 10.3760/cma.j.issn.0412⁃ 4030.2013.09.003.
|
[4] |
Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis[J]. Cutis, 2018,101(1):E15⁃E21.
|
[5] |
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis[J]. J Am Acad Dermatol, 2014,71(2):278⁃283. doi: 10.1016/j.jaad.2014.04.044.
|
[6] |
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions[J]. J Clin Invest, 2018,128(3):985⁃996. doi: 10.1172/JCI93349.
|
[7] |
Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000,115(2):149⁃153. doi: 10.1046/j.1523⁃1747. 2000.00061.x.
|
[8] |
Syed D, Iqbal O, Mosier M, et al. Elevated endocan levels and its association with clinical severity in Stevens⁃Johnson Syndrome and toxic epidermal necrolysis[J]. Int Angiol, 2015,34(5):483⁃488.
|
[9] |
Al⁃Shouli S, Abouchala N, Bogusz MJ, et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab[J]. Acta Derm Venereol, 2005,85(6):534⁃535. doi: 10.1080/00015550510037062.
|
[10] |
经晶, 路丹丹, 施辛, 等. 肿瘤坏死因子α拮抗剂治疗Stevens⁃Johnson综合征17例[J]. 中华皮肤科杂志, 2016,49(7):465⁃468. doi: 10.3760/cma.j.issn.0412⁃4030.2016.07.004.
|
[11] |
Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis preceding skin detachment[J]. J Allergy Clin Immunol, 2008,122(5):992⁃1000. doi: 10.1016/j.jaci.2008.06.013.
|
[12] |
de Araujo E, Dessirier V, Laprée G, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis[J]. Exp Dermatol, 2011,20(2):107⁃112. doi: 10.1111/j.1600⁃0625.2010. 01176.x.
|
[13] |
Wang F, Ye Y, Luo ZY, et al. Diverse expression of TNF⁃α and CCL27 in serum and blister of Stevens⁃Johnson syndrome/toxic epidermal necrolysis[J]. Clin Transl Allergy, 2018,8:12. doi: 10.1186/s13601⁃018⁃0199⁃6.
|
[14] |
Berthold E, Månsson B, Gullstrand B, et al. Tumour necrosis factor⁃α/etanercept complexes in serum predict long⁃term efficacy of etanercept treatment in seronegative rheumatoid arthritis[J]. Scand J Rheumatol, 2018,47(1):22⁃26. doi: 10. 1080/03009742.2017.1290822.
|
[15] |
Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti⁃TNF⁃alpha treatment[J]. J Allergy Clin Immunol, 2005,116(4):923⁃924. doi: 10.1016/j.jaci. 2005.06.029.
|
[16] |
Chahal D, Aleshin M, Turegano M, et al. Vaccine⁃induced toxic epidermal necrolysis: a case and systematic review[J]. Dermatol Online J, 2018,24(1). pii: 13030/qt7qn5268s.
|
[17] |
Wang R, Zhong S, Tu P, et al. Rapid remission of Stevens⁃Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature[J]. Dermatol Ther, 2019,32(4):e12832. doi: 10.1111/dth.12832.
|
[18] |
Famularo G, Di Dona B, Canzona F, et al. Etanercept for toxic epidermal necrolysis[J]. Ann Pharmacother, 2007,41(6):1083⁃1084. doi: 10.1345/aph.1K001.
|